Biological Therapies in Inflammatory Myopathies
Idiopathic inflammatory myopathies (IIM) are a rare group of disorders that feature progressive immune-mediated skeletal muscle destruction along with skin, lung, and joint involvement. Management of IIMs necessitates glucocorticoid therapy followed by conventional steroid-sparing agents to control...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Rambam Health Care Campus
2023-04-01
|
| Series: | Rambam Maimonides Medical Journal |
| Subjects: | |
| Online Access: | https://www.rmmj.org.il/issues/57/1622/manuscript |
| _version_ | 1797836128076693504 |
|---|---|
| author | Abd El Haleem Natour Shaye Kivity |
| author_facet | Abd El Haleem Natour Shaye Kivity |
| author_sort | Abd El Haleem Natour |
| collection | DOAJ |
| description | Idiopathic inflammatory myopathies (IIM) are a rare group of disorders that feature progressive immune-mediated skeletal muscle destruction along with skin, lung, and joint involvement. Management of IIMs necessitates glucocorticoid therapy followed by conventional steroid-sparing agents to control disease activity. In the settings of refractory myositis or life-threatening manifestations, e.g. lung involvement or oropharyngeal dysphagia, second-line therapies are needed to minimize disease burden, avoid end-organ damage and steroid toxicity, and decrease mortality. These therapies may include biological disease-modifying antirheumatic drugs (bDMARDs), and to a lesser extent, targeted synthetic disease-modifying antirheumatic drugs (TSD). This article reviews the current use of bDMARDs, e.g. intravenous immunoglobulin and rituximab, and a TSD—Janus kinase inhibitors (JAKI)—along with their indications, efficacy, and safety in managing IIM. |
| first_indexed | 2024-04-09T15:03:41Z |
| format | Article |
| id | doaj.art-108a95c0eba5495794861d2654fa87d9 |
| institution | Directory Open Access Journal |
| issn | 2076-9172 |
| language | English |
| last_indexed | 2024-04-09T15:03:41Z |
| publishDate | 2023-04-01 |
| publisher | Rambam Health Care Campus |
| record_format | Article |
| series | Rambam Maimonides Medical Journal |
| spelling | doaj.art-108a95c0eba5495794861d2654fa87d92023-04-30T17:42:25ZengRambam Health Care CampusRambam Maimonides Medical Journal2076-91722023-04-01142e000810.5041/RMMJ.10495Biological Therapies in Inflammatory MyopathiesAbd El Haleem Natour0Shaye Kivity1Rheumatology Unit, Meir Medical Center, Kfar Saba, Israel; and Department of Internal Medicine A, Meir Medical Center, Kfar Saba, IsraelRheumatology Unit, Meir Medical Center, Kfar Saba, IsraelIdiopathic inflammatory myopathies (IIM) are a rare group of disorders that feature progressive immune-mediated skeletal muscle destruction along with skin, lung, and joint involvement. Management of IIMs necessitates glucocorticoid therapy followed by conventional steroid-sparing agents to control disease activity. In the settings of refractory myositis or life-threatening manifestations, e.g. lung involvement or oropharyngeal dysphagia, second-line therapies are needed to minimize disease burden, avoid end-organ damage and steroid toxicity, and decrease mortality. These therapies may include biological disease-modifying antirheumatic drugs (bDMARDs), and to a lesser extent, targeted synthetic disease-modifying antirheumatic drugs (TSD). This article reviews the current use of bDMARDs, e.g. intravenous immunoglobulin and rituximab, and a TSD—Janus kinase inhibitors (JAKI)—along with their indications, efficacy, and safety in managing IIM.https://www.rmmj.org.il/issues/57/1622/manuscriptabataceptbdmardsidiopathic inflammatory myopathiesivigjakirituximab |
| spellingShingle | Abd El Haleem Natour Shaye Kivity Biological Therapies in Inflammatory Myopathies Rambam Maimonides Medical Journal abatacept bdmards idiopathic inflammatory myopathies ivig jaki rituximab |
| title | Biological Therapies in Inflammatory Myopathies |
| title_full | Biological Therapies in Inflammatory Myopathies |
| title_fullStr | Biological Therapies in Inflammatory Myopathies |
| title_full_unstemmed | Biological Therapies in Inflammatory Myopathies |
| title_short | Biological Therapies in Inflammatory Myopathies |
| title_sort | biological therapies in inflammatory myopathies |
| topic | abatacept bdmards idiopathic inflammatory myopathies ivig jaki rituximab |
| url | https://www.rmmj.org.il/issues/57/1622/manuscript |
| work_keys_str_mv | AT abdelhaleemnatour biologicaltherapiesininflammatorymyopathies AT shayekivity biologicaltherapiesininflammatorymyopathies |